PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

Filip Janku, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha-Paul, J. Jack Lee, Rajyalakshmi Luthra, Apostolia M. Tsimberidou, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

244 Scopus citations

Fingerprint

Dive into the research topics of 'PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences